01:50 PM EDT, 07/29/2024 (MT Newswires) -- CervoMed ( CRVO ) said Monday baseline data from a phase 2a trial of neflamapimod in patients with dementia with Lewy bodies showed that plasma glial fibrillary acidic protein was highly correlated to scores on the Clinical Dementia Rating Sum of Boxes, with the protein shown to increase with neurodegenerative progression.

The trial results also showed that neflamapimod treatment led to significant reduction in plasma glial fibrillary acidic protein levels in patients with dementia with Lewy bodies compared with placebo, the company said. The trial was featured in a poster presentation at the Alzheimer's Association International conference in Philadelphia.

"Recent developments in the field support the use of plasma GFAP to evaluate the therapeutic effects on DLB-specific disease processes, and baseline data from...our Phase 2a trial, further validate the utility of this biomarker," said CEO John Alam.

The stock was up about 1.6% in recent trading.

Price: 14.25, Change: +0.22, Percent Change: +1.57